NeoPharm CO., LTD. (KOSDAQ:092730)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,170
+750 (4.57%)
Jun 9, 2026, 3:30 PM KST
Market Cap268.56B +22.5%
Revenue (ttm)132.18B +11.1%
Net Income27.82B +20.6%
EPS1,778.81 +20.6%
Shares Out 15.64M
PE Ratio9.65
Forward PE8.29
Dividend750.00 (4.57%)
Ex-Dividend DateDec 29, 2025
Volume47,302
Open16,840
Previous Close16,420
Day's Range16,500 - 17,430
52-Week Range13,820 - 22,650
Beta0.56
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So... [Read more]

Founded 2000
Employees 178
Stock Exchange KOSDAQ
Ticker Symbol 092730
Full Company Profile

Financial Performance

In 2025, NeoPharm CO., LTD.'s revenue was 132.18 billion, an increase of 11.07% compared to the previous year's 119.01 billion. Earnings were 27.82 billion, an increase of 20.63%.

Financial Statements